VIRIDIAN THERAPEUTICS INC (VRDN)
US92790C1045 - Common Stock
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
Viridian Therapeutics is Now Oversold (VRDN)
Investors Snatch VRDN 28.9% Lower Than Its Secondary Stock Offering
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
/PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) ("Viridian") on behalf of the company's...
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
Although cheap stocks under $20 represent a higher-risk profile, the rewards could be massive if the spotlight shines on them.
Commit To Purchase Viridian Therapeutics At $12.50, Earn 37% Annualized Using Options
VRDN Makes Bullish Cross Above Critical Moving Average
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
Viridian Therapeutics Breaks Above 200-Day Moving Average - Bullish for VRDN
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Investors Grab VRDN 7.2% Lower Than Its Secondary Stock Offering
VRDN Crosses Below Key Moving Average Level
Viridian Therapeutics stock slides on pricing stock offering to raise $150 million
Viridian Therapeutics (VRDN) announces the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. The company is sellin
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
Viridian Therapeutics starts public offering of common and preferred stock (NASDAQ:VRDN)
Viridian Therapeutics announces a public offering of common stock and Series B preferred stock to raise funds for clinical development programs.
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Viridian Therapeutics Breaks Above 200-Day Moving Average - Bullish for VRDN
Viridian Therapeutics files to sell 15.02M shares for holders (NASDAQ:VRDN)
Viridian Therapeutics files a prospectus for the resale of 15.02M shares by selling stockholders, not an offer to sell these securities.
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
Viridian Therapeutics GAAP EPS of -$1.09 beats by $0.08, revenue of $0.07M misses by $0.03M (NASDAQ:VRDN)
Viridian Therapeutics beats Q3 earnings expectations with a GAAP EPS of -$1.09, however, revenue misses by $0.03M.
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
Viridian Therapeutics appoints Stephen Mahoney as CEO (NASDAQ:VRDN)
I wrote an article about Viridian Therapeutics appointing a new CEO and entering into a private placement deal for $185M.